169 related articles for article (PubMed ID: 23139156)
1. Channel sialic acids limit hERG channel activity during the ventricular action potential.
Norring SA; Ednie AR; Schwetz TA; Du D; Yang H; Bennett ES
FASEB J; 2013 Feb; 27(2):622-31. PubMed ID: 23139156
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of the short QT N588K mutation at 37 degrees C on hERG K+ channel current during ventricular, Purkinje fibre and atrial action potentials: an action potential clamp study.
McPate MJ; Zhang H; Adeniran I; Cordeiro JM; Witchel HJ; Hancox JC
J Physiol Pharmacol; 2009 Mar; 60(1):23-41. PubMed ID: 19439805
[TBL] [Abstract][Full Text] [Related]
3. 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.
Gordon E; Lozinskaya IM; Lin Z; Semus SF; Blaney FE; Willette RN; Xu X
Mol Pharmacol; 2008 Mar; 73(3):639-51. PubMed ID: 18042732
[TBL] [Abstract][Full Text] [Related]
4. The human ether-a-go-go-related gene (hERG) current inhibition selectively prolongs action potential of midmyocardial cells to augment transmural dispersion.
Yasuda C; Yasuda S; Yamashita H; Okada J; Hisada T; Sugiura S
J Physiol Pharmacol; 2015 Aug; 66(4):599-607. PubMed ID: 26348084
[TBL] [Abstract][Full Text] [Related]
5. In-silico modeling of glycosylation modulation dynamics in hERG ion channels and cardiac electrical signals.
Du D; Yang H; Norring SA; Bennett ES
IEEE J Biomed Health Inform; 2014 Jan; 18(1):205-14. PubMed ID: 24403418
[TBL] [Abstract][Full Text] [Related]
6. Sialic acids attached to N- and O-glycans within the Nav1.4 D1S5-S6 linker contribute to channel gating.
Ednie AR; Harper JM; Bennett ES
Biochim Biophys Acta; 2015 Feb; 1850(2):307-17. PubMed ID: 25450184
[TBL] [Abstract][Full Text] [Related]
7. N-glycans modulate K(v)1.5 gating but have no effect on K(v)1.4 gating.
Schwetz TA; Norring SA; Bennett ES
Biochim Biophys Acta; 2010 Mar; 1798(3):367-75. PubMed ID: 19961828
[TBL] [Abstract][Full Text] [Related]
8. Electrophysiologic characterization of a novel hERG channel activator.
Su Z; Limberis J; Souers A; Kym P; Mikhail A; Houseman K; Diaz G; Liu X; Martin RL; Cox BF; Gintant GA
Biochem Pharmacol; 2009 Apr; 77(8):1383-90. PubMed ID: 19426677
[TBL] [Abstract][Full Text] [Related]
9. The N588K-HERG K+ channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37 degrees C.
McPate MJ; Duncan RS; Milnes JT; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2005 Aug; 334(2):441-9. PubMed ID: 16011830
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.
Kang J; Chen XL; Wang H; Ji J; Cheng H; Incardona J; Reynolds W; Viviani F; Tabart M; Rampe D
Mol Pharmacol; 2005 Mar; 67(3):827-36. PubMed ID: 15548764
[TBL] [Abstract][Full Text] [Related]
11. A novel missense mutation causing a G487R substitution in the S2-S3 loop of human ether-à-go-go-related gene channel.
Kinoshita K; Yamaguchi Y; Nishide K; Kimoto K; Nonobe Y; Fujita A; Asano K; Tabata T; Mori H; Inoue H; Hata Y; Fukurotani K; Nishida N
J Cardiovasc Electrophysiol; 2012 Nov; 23(11):1246-53. PubMed ID: 22764740
[TBL] [Abstract][Full Text] [Related]
12. Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel.
Ridley JM; Milnes JT; Hancox JC; Witchel HJ
J Mol Cell Cardiol; 2006 Jan; 40(1):107-18. PubMed ID: 16288909
[TBL] [Abstract][Full Text] [Related]
13. C-terminal HERG (LQT2) mutations disrupt IKr channel regulation through 14-3-3epsilon.
Choe CU; Schulze-Bahr E; Neu A; Xu J; Zhu ZI; Sauter K; Bähring R; Priori S; Guicheney P; Mönnig G; Neapolitano C; Heidemann J; Clancy CE; Pongs O; Isbrandt D
Hum Mol Genet; 2006 Oct; 15(19):2888-902. PubMed ID: 16923798
[TBL] [Abstract][Full Text] [Related]
14. Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator.
Zeng H; Lozinskaya IM; Lin Z; Willette RN; Brooks DP; Xu X
J Pharmacol Exp Ther; 2006 Nov; 319(2):957-62. PubMed ID: 16928897
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide.
Paul AA; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2001 Feb; 280(5):1243-50. PubMed ID: 11162661
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of HERG K+ currents by Cd2+ destabilization of the inactivated state.
Johnson JP; Balser JR; Bennett PB
Biophys J; 1999 Nov; 77(5):2534-41. PubMed ID: 10545354
[TBL] [Abstract][Full Text] [Related]
17. Sialic acids attached to O-glycans modulate voltage-gated potassium channel gating.
Schwetz TA; Norring SA; Ednie AR; Bennett ES
J Biol Chem; 2011 Feb; 286(6):4123-32. PubMed ID: 21115483
[TBL] [Abstract][Full Text] [Related]
18. Time course and voltage dependence of expressed HERG current compared with native "rapid" delayed rectifier K current during the cardiac ventricular action potential.
Hancox JC; Levi AJ; Witchel HJ
Pflugers Arch; 1998 Nov; 436(6):843-53. PubMed ID: 9799397
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the HERG channel by droperidol depends on channel gating and involves the S6 residue F656.
Luo T; Luo A; Liu M; Liu X
Anesth Analg; 2008 Apr; 106(4):1161-70, table of contents. PubMed ID: 18349188
[TBL] [Abstract][Full Text] [Related]
20. Mutant MiRP1 subunits modulate HERG K+ channel gating: a mechanism for pro-arrhythmia in long QT syndrome type 6.
Lu Y; Mahaut-Smith MP; Huang CL; Vandenberg JI
J Physiol; 2003 Aug; 551(Pt 1):253-62. PubMed ID: 12923204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
